11 completed, 2 recruiting, 1 active not recruiting. 6 Phase 3, 3 Phase 2, 2 Not applicable, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 5, Recruiting 1 |
| Phase 2 | 3 | Completed 3 |
| Not applicable | 2 | Active not recruiting 1, Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Santen SAS: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group Microshunt XI - Primary Open Angle Glaucoma | Recruiting | Santen SAS | 112 | 2026-03-19 | 2026-07-16 | |
| Observational Survey Study on the Impact of Myopia and Its Complications on Quality of Life. Non-Intervention - Myopia | Completed | Santen SAS | 344 | 2025-07-29 | 2026-05-22 | |
| LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis. STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers, Placebo (0% Oxymetazoline Hydrochloride) eye drops in single dose containers - Acquired Blepharophimosis | Phase 3 | Recruiting | Santen SAS | 234 | 2024-12-30 | 2026-05-04 |
| 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis Cationorm Pro, Vismed - Dry Eye Syndromes | Not applicable | Completed | Santen SAS | 83 | 2021-09-30 | 2025-05-21 |
| 3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis Alocross 0.2% Unit Dose, Vismed - Dry Eye Syndromes | Not applicable | Active not recruiting | Santen SAS | 80 | 2021-05-11 | 2025-05-21 |
| 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin) Open-label Ikervis, Masked Ikervis, Vehicle Comparator: Masked Vehicle - Dry Eye Disease With Severe Keratitis | Phase 3 | Completed | Santen SAS | 350 | 2019-05-31 | 2024-08-28 |
| A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension DE-130A, Xalatan®, DE-130A/DE-130A - Open-Angle Glaucoma or Ocular Hypertension, Ocular Surface Disease | Phase 3 | Completed | Santen SAS | 386 | 2019-04-10 | 2024-05-28 |
| Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis 1mg/mL ciclosporin - Keratitis | Phase 4 | Completed | Santen SAS | 17 | 2017-03-28 | 2024-04-18 |
| Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis NOVA22007 ''Ciclosporin'', Placebo - Vernal Keratoconjunctivitis | Phase 3 | Completed | Santen SAS | 169 | 2013-04-29 | 2022-03-28 |
| Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease Latanoprost, Travatan Z - Glaucoma, Ocular Hypertension | Phase 2 | Completed | Santen SAS | 105 | 2010-11-01 | 2016-06-06 |
| NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye NOVA22007 ''Cyclosporine'', vehicle/placebo - Dry Eye | Phase 2 | Completed | Santen SAS | 132 | 2008-08-01 | 2016-06-06 |
| Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy NOVA63035 "Corticosteroid" - Diabetic Macular Edema | Phase 1 | Completed | Santen SAS | 20 | 2008-04-01 | 2015-05-27 |
| Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome NOVA22007 (Ciclosporin 0.1%), NOVA22007 - Moderate to Severe Dry Eye Syndrome | Phase 3 | Completed | Santen SAS | 482 | 2007-09-01 | 2010-07-16 |
| Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC) Cyclosporine NOVA22007 0.05%, Cyclosporine NOVA22007 0.1%, Vehicle - Conjunctivitis, Vernal | Phase 2 / Phase 3 | Completed | Santen SAS | 118 | 2006-05-01 | 2021-12-14 |
Dry Eye Syndromes (3) · Conjunctivitis, Allergic (2) · Glaucoma, Open-Angle (2) · Ocular Hypertension (2) · Diabetes Mellitus (1) · Diabetic Retinopathy (1) · Glaucoma (1) · Hypersensitivity (1) · Keratitis (1) · Lymphoma, Follicular (1) · Myopia (1)
Latanoprost (2) · Cyclosporine (1) · Ophthalmic Solutions (1) · Oxymetazoline (1) · Travoprost (1)
France (10) · Spain (6) · Italy (5) · Germany (4) · United States (4) · Poland (3) · United Kingdom (3) · Czechia (2) · Hungary (2) · Netherlands (2) · Portugal (2) · Austria (1) · Belgium (1) · Croatia (1) · Denmark (1)
Christophe Baudouin, Pf. (1) · David BenEzra, Pf (1) · Jean-Sebastien Garrigue, PhD (1)